Stefan Hart

3.5k citations

30 papers · 2.7k indexed · 1 hit paper · h-index 23

Impact in

Genetics top 2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Oncology top 2%
- HER2/EGFR in Cancer Research
- Cytokine Signaling Pathways and Interactions

Papers in

Genetics 10
- Myeloproliferative Neoplasms: Diagnosis and Treatment 7
- Chronic Lymphocytic Leukemia Research 4
Hematology 9
- Acute Myeloid Leukemia Research 5
- Chronic Myeloid Leukemia Treatments 5

Co-authors: Oliver M. Fischer A. Ullrich Axel Ullrich Norbert Prenzel S. Streit Andreas Gschwind Kantharaj Ethirajulu Ramesh Jayaraman
Journals: Blood (3 papers)Journal of Hepatology (2 papers)Cancer Research (2 papers)Leukemia (2 papers)Blood Cancer Journal (2 papers)
Partner nations: Singapore Germany United States

In The Last Decade

Stefan Hart

29 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. 2001 · 553 citations

Peers

Countries citing papers authored by Stefan Hart

Since Specialization

Citations

This map shows the geographic impact of Stefan Hart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Hart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Hart more than expected).

Fields of papers citing papers by Stefan Hart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Hart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Hart. The network helps show where Stefan Hart may publish in the future.

Co-authors

The 25 scholars most cited alongside Stefan Hart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stefan Hart Line = papers co-authored together Stefan Hart links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim Oncotarget ·Nurulhuda Mustafa, 段卉, Michael Reichenbach, Chonglei Bi, Tae‐Hoon Chung, Stefan Hart, Wee Joo Chng	2017	6
2	Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma Cancer Investigation ·Alexander Heifetz Michael P Mazanetz, Bernice H. Wong, Dachuan Huang, Jing Tan, Choon Kiat Ong, Masatsugu Iwamura, Stefan Hart, Markus Dangl, Markus Thomas, Bin Tean Teh	2015	11
3	Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602 Journal of Chemical Information and Modeling ·Anders Poulsen, Harish Nagaraj, Muneeb ur Rehman, Stéphanie Blanchard, Bentley B. Rodrigue, Й Меннике, Haishan Wang, Stefan Hart, Kee Chuan Goh, Brian Dymock, Meredith Williams	2014	27
4	Scalable Spheroid Model of Human Hepatocytes for Hepatitis C Infection and Replication Molecular Pharmaceutics ·Abhishek Ananthanarayanan, Bramasta Nugraha, Miriam Triyatni, Stefan Hart, وجدان مصلح الحربي, Hanry Yu	2014	28
5	Reduction of HBV replication prolongs the early immunological response to IFNα therapy Journal of Hepatology ·Anthony T. Tan, Long Hoàng, Daniel J. Chin, Erik Rasmussen, Uri Lopatin, Stefan Hart, Hans Bitter, Tom Chu, Lore Gruenbaum, Е В Азизова, Hua Zhong, Ed Gane, Seng Gee Lim, Wan Cheng Chow, Pei‐Jer Chen, Rosemary Petric, Antonio Bertoletti, Martin L. Hibberd	2013	62
6	A Novel and Highly Selective Dual PI3K/mTOR Kinase Inhibitor VS-5584, Shows Promising Therapeutic Potential For The Treatment Of Multiple Myeloma Blood ·Nurulhuda Mustafa, Stefan Hart, Wee Joo Chng	2013	1
7	The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML Blood Cancer Journal ·Veronica Novotny‐Diermayr, Stefan Hart, Jang-Sung Park, Albert Cheong, Fitriananda An Nur, Hannes Hentze, Mohammed Khysar Pasha, Ramesh Jayaraman, Kantharaj Ethirajulu, Edwin Permana	2012	87
8	TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties Leukemia ·Jang-Sung Park, Veronica Novotny‐Diermayr, Stefan Hart, Fitriananda An Nur, Yung Kiang Loh, Albert Cheong, Yuxin Tan, Sp.S Prof.Dr.dr. Krt. Soejono Prawirohadikusumo, Ramesh Jayaraman, Anthony D. William, Eric T. Sun, Brian Dymock, Kiat Hoe Ong, Kantharaj Ethirajulu, Francis Burrows, J M Wood	2011	105
9	SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies Leukemia ·Stefan Hart, Jang-Sung Park, Veronica Novotny‐Diermayr, Wen Fu-rong, Hannes Hentze, Yuxin Tan, Babita Madan, I. B., Yung Kiang Loh, Fitriananda An Nur, Anthony D. William, Derik Clive R., Anders Poulsen, Ramesh Jayaraman, Kiat Hoe Ong, Kantharaj Ethirajulu, Brian Dymock, Zheng Yu-mei	2011	152
10	SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer Molecular Cancer Therapeutics ·Veronica Novotny‐Diermayr, Kanda Sangthongpitag, Katsushi Yoshimitsu, Xiaofeng Wu, Nina Sausgruber, Pauline Yeo, Gediminas Greicius, Sven Pettersson, Nika Barbarić, Yung Kiang Loh, Zahid Bonday, Kee Chuan Goh, Hannes Hentze, Stefan Hart, Haishan Wang, Kantharaj Ethirajulu, Jeanette M. Wood	2010	109
11	The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells Oncogene ·Andreas Roidl, Michaela Jacob, Willy Wong, IN Ru-mou, Gözen Güner Aktaş, 和将松本, S. Streit, Jens E. Ruhe, Stefan Hart, A. Ullrich, Han Kiat Ho	2009	46
12	The Effects of SB1518, a Novel Oral JAK2 Inhibitor, On Ex Vivo Expanded PV Erythroid Progenitors Correlate with Clinical Observations. Blood ·Kee Chuan Goh, Stefan Hart, Yong Tan, I. B., Kiat Hoe Ong, Jeanette M. Wood	2009	1
13	Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention Journal of Hepatology ·Han Kiat Ho, Sharon Pok, Sylvia Streit, Jens E. Ruhe, Stefan Hart, Kah Suan Lim, Hooi Linn Loo, Myat Oo Aung, Seng Gee Lim, Axel Ullrich	2008	154
14	Dissecting the Epidermal Growth Factor Receptor Signal Transactivation Pathway Humana Press eBooks ·Oliver M. Fischer, Stefan Hart, Axel Ullrich	2006	30
15	GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways Biological Chemistry ·Stefan Hart, Oliver M. Fischer, Norbert Prenzel, Xiyi Lai, Matthias Schneider, Lothar Hennighausen, Axel Ullrich	2005	82
16	Mammary Gland Remodeling Depends on gp130 Signaling through Stat3 and MAPK Journal of Biological Chemistry ·Ling Zhao, Stefan Hart, JrGang Cheng, J. Joseph Melenhorst, Brian Bierie, Matthias Ernst, Colin L. Stewart, Fred Schaper, Peter C. Heinrich, Axel Ullrich, Gertraud W. Robinson, Lothar Hennighausen	2004	43
17	Oxidative and Osmotic Stress Signaling in Tumor Cells Is Mediated by ADAM Proteases and Heparin-Binding Epidermal Growth Factor Molecular and Cellular Biology ·Oliver M. Fischer, Stefan Hart, Andreas Gschwind, Norbert Prenzel, Axel Ullrich	2004	127
18	Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor Cancer Research ·Stefan Hart, Oliver M. Fischer, Axel Ullrich	2004	240
19	Beyond Herceptin and Gleevec Current Opinion in Chemical Biology ·Oliver M. Fischer, Sylvia Streit, Stefan Hart, Axel Ullrich	2003	66
20	The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocrine Related Cancer ·Norbert Prenzel, Oliver M. Fischer, S. Streit, Stefan Hart, A. Ullrich Hit paper breakdown →	2001	553

About Stefan Hart

Stefan Hart is a scholar working on Genetics, Hematology, Oncology, Hepatology and Physiology, having authored 30 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Acute Myeloid Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers), HER2/EGFR in Cancer Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Genetics (413 citations), Oncology (1.0k citations), Hematology (326 citations), Immunology and Allergy (143 citations) and Molecular Biology (1.4k citations). Stefan Hart has collaborated with scholars based in Singapore, Germany and United States. Frequent co-authors include Oliver M. Fischer, A. Ullrich, Axel Ullrich, Norbert Prenzel, S. Streit, Andreas Gschwind, Kantharaj Ethirajulu, Ramesh Jayaraman, Veronica Novotny‐Diermayr and Sylvia Streit. Their work appears in journals such as Blood, Journal of Hepatology, Cancer Research, Leukemia and Blood Cancer Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact